DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	1

告示番号

疾患名（ページ内リンク）

臨床試験数

特発性間質性肺炎

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03949530 (ClinicalTrials.gov)	April 16, 2019	6/5/2019	A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis	IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)	Healthy Volunteers;Idiopathic Pulmonary Fibrosis	Drug: IDL-2965 Oral Capsule;Drug: Placebos	Indalo Therapeutics, Inc.	NULL	Terminated	18 Years	60 Years	All	6	Phase 1	United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03949530
(ClinicalTrials.gov)

April 16, 2019

6/5/2019

A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Healthy Volunteers;Idiopathic Pulmonary Fibrosis

Drug: IDL-2965 Oral Capsule;Drug: Placebos

Indalo Therapeutics, Inc.

NULL

Terminated

18 Years

60 Years

All

Phase 1

United Kingdom